title: Diagnostic and Therapeutic Challenges.
authors.forename: Kalpana
authors.initials: K
authors.lastname: Badami
authors.forename: Aliya
authors.initials: A
authors.lastname: Sultana
authors.forename: Babi
authors.initials: B
authors.lastname: Sinha
authors.forename: Raghavendra
authors.initials: R
authors.lastname: Ijeri
authors.forename: Chaitra
authors.initials: C
authors.lastname: Jayadev
authors.forename: Stephen H
authors.initials: SH
authors.lastname: Tsang
mesh_terms: D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004596:Electroretinography; D015785:Eye Diseases, Hereditary / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D012162:Retinal Degeneration / Q000175:diagnosis / Q000188:drug therapy; D058456:Retinal Telangiectasis / Q000175:diagnosis* / Q000188:drug therapy; D012174:Retinitis Pigmentosa / Q000175:diagnosis* / Q000188:drug therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014786:Vision Disorders / Q000175:diagnosis / Q000188:drug therapy; D014792:Visual Acuity; D014823:Vitreous Hemorrhage / Q000175:diagnosis* / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab